FIELD: biochemistry.
SUBSTANCE: invention relates to an antibody or its antigen-binding fragment specifically binding to CD37, as well as to an immunoconjugate thereof, a diagnostic reagent and a pharmaceutical composition. Also disclosed is an isolated cell producing said antibody or antigen-binding fragment thereof, which is a hybrid of ATCC number PTA-10664, deposited in ATCC on February 18, 2010, as well as an isolated polynucleotide, coding a heavy chain variable region and a light chain variable region of said antibody or antigen-binding fragment thereof. Invention also relates to use of an antibody or antigen-binding fragment thereof, as well as to use of the immunoconjugate in the manufacture of a medicament for the treatment of an oncological disease characterized by the presence of CD37-expressing cells.
EFFECT: invention enables effective treatment of oncological disease characterized by the presence of CD37-expressing cells.
33 cl, 32 dwg, 12 tbl, 17 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHODS FOR PREPARING ANTIBODY-DRUG CONJUGATE COMPOSITIONS | 2015 |
|
RU2741470C2 |
| ANTIBODIES AGAINST FOLIC ACID RECEPTOR 1, THEIR IMMUNOCONJUGATES AND USE | 2011 |
|
RU2740479C2 |
| CONJUGATES OF ANTIBODY TO CCR7 AND DRUG | 2018 |
|
RU2777662C2 |
| SITE-SPECIFIC HER2 ANTIBODY-DRUG CONJUGATES | 2016 |
|
RU2745565C2 |
| ANTIBODIES AND ANTIBODY FRAGMENTS FOR SITE-SPECIFIC CONJUGATION | 2016 |
|
RU2757815C2 |
| ANTI-CD79B ANTIBODIES, IMMUNOCONJUGATES AND METHODS FOR THEIR USE | 2019 |
|
RU2791984C2 |
| PROTEIN BINDING WITH NKG2D, CD16 AND WITH TUMOR-SPECIFIC ANTIGEN | 2018 |
|
RU2826991C2 |
| MAITANZINOID DERIVATIVES WITH SELF-SPLITTING PEPTIDE LINKERS AND THEIR CONJUGATES | 2018 |
|
RU2765098C2 |
| BISPECIFIC ANTIGEN-BINDING CONSTRUCTS AGAINST HER2 | 2014 |
|
RU2737882C2 |
| PHARMACEUTICAL COMPOSITION FOR TREATMENT AND/OR PREVENTION OF MALIGNANT TUMOR | 2017 |
|
RU2766586C2 |
